Safety and Efficacy of Apremilast Through 104 Weeks in Patients swith Moderate-to-Severe Psoriasis Who Continued on Apremilast or Switched from Etanercept Treatment in the LIBERATE Study

Main Article Content

Kristian Reich
Mark Goodfield
Lawrence Green
Kristine Nograles
Eugenia Levi
Richard GB Langley


safety, efficacy, apremilast, psoriasis


Abstract Not Available


Disclosure: Study supported by Celgene.

Most read articles by the same author(s)

1 2 3 4 5 6 > >>